- Home
- IVVD vs ZURA Comparison
IVVD vs ZURA Comparison
Compare IVVD & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- ZURA
- Stock Information
- Founded
- IVVD 2020
- ZURA 2022
- Country
- IVVD United States
- ZURA United States
- Employees
- IVVD N/A
- ZURA N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IVVD Health Care
- ZURA Health Care
- Exchange
- IVVD Nasdaq
- ZURA Nasdaq
- Market Cap
- IVVD 69.0M
- ZURA 76.6M
- IPO Year
- IVVD 2021
- ZURA N/A
- Fundamental
- Price
- IVVD $0.93
- ZURA $1.01
- Analyst Decision
- IVVD Strong Buy
- ZURA Buy
- Analyst Count
- IVVD 3
- ZURA 7
- Target Price
- IVVD $5.85
- ZURA $14.33
- AVG Volume (30 Days)
- IVVD 3.1M
- ZURA 517.4K
- Earning Date
- IVVD 05-15-2025
- ZURA 05-08-2025
- Dividend Yield
- IVVD N/A
- ZURA N/A
- EPS Growth
- IVVD N/A
- ZURA N/A
- EPS
- IVVD N/A
- ZURA N/A
- Revenue
- IVVD $36,688,000.00
- ZURA N/A
- Revenue This Year
- IVVD $606.63
- ZURA N/A
- Revenue Next Year
- IVVD $83.30
- ZURA N/A
- P/E Ratio
- IVVD N/A
- ZURA N/A
- Revenue Growth
- IVVD N/A
- ZURA N/A
- 52 Week Low
- IVVD $0.35
- ZURA $0.97
- 52 Week High
- IVVD $2.74
- ZURA $5.50
- Technical
- Relative Strength Index (RSI)
- IVVD 63.94
- ZURA 35.69
- Support Level
- IVVD $0.81
- ZURA $0.99
- Resistance Level
- IVVD $1.00
- ZURA $1.06
- Average True Range (ATR)
- IVVD 0.12
- ZURA 0.08
- MACD
- IVVD 0.02
- ZURA -0.01
- Stochastic Oscillator
- IVVD 64.76
- ZURA 9.02
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.